Urakami K, Mori M, Wada K, Kowa H, Takeshima T, Arai H, Sasaki H, Kanai M, Shoji M, Ikemoto K, Morimatsu M, Hikasa C, Nakashima K
Division of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan.
Neurosci Lett. 1999 Jan 8;259(2):127-9. doi: 10.1016/s0304-3940(98)00923-9.
Many clinical and pathological discussions have been focused on the difficulty of differential diagnosis between corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) in recent years. This study was conducted to evaluate the usefulness of tau proteins in cerebrospinal fluid (CSF) for the differentiation of these two diseases. Subjects consisted of 10 patients with CBD (four males and six females with a mean age of 67.9+/-5.8 years), 12 patients with PSP (eight males and four females with a mean age of 62.6+/-5.8 years) and 36 control subjects (CTL) (16 males and 20 females with a mean age of 65.8+/-9.9 years). The CBD group included patients with probable CBD, while all the patients in the PSP group satisfied the diagnostic criteria developed by the National Institute of Neurological Disorders and Stroke and Society for PSP (NINDS-SPSP). CSF tau proteins were measured with the sandwich ELISA method (Innogenetics, Belgium). The CSF tau protein level was 320.1+/-86.5 pg/ml in the CBD group, 151.5+/-52.7 pg/ml in the PSP group and 128.7+/-91.7 pg/ml in the CTL group. Significant differences were noted in tau protein levels between the CBD group and both the PSP group (P<0.001) and the CTL group (P<0.005). We suggested that the measurement of CSF tau proteins may be useful for the differentiation between CBD and PSP.
近年来，许多临床和病理学讨论都聚焦于皮质基底节变性（CBD）和进行性核上性麻痹（PSP）之间鉴别诊断的困难。本研究旨在评估脑脊液（CSF）中tau蛋白对这两种疾病鉴别的有用性。研究对象包括10例CBD患者（4例男性，6例女性，平均年龄67.9±5.8岁）、12例PSP患者（8例男性，4例女性，平均年龄62.6±5.8岁）和36例对照者（CTL）（16例男性，20例女性，平均年龄65.8±9.9岁）。CBD组包括可能患有CBD的患者，而PSP组的所有患者均符合美国国立神经疾病与中风研究所和PSP协会（NINDS-SPSP）制定的诊断标准。采用夹心酶联免疫吸附测定法（ELISA）（比利时Innogenetics公司）检测脑脊液tau蛋白。CBD组脑脊液tau蛋白水平为320.1±86.5 pg/ml，PSP组为151.5±52.7 pg/ml，CTL组为128.7±91.7 pg/ml。CBD组与PSP组（P<0.001）和CTL组（P<0.005）的tau蛋白水平均存在显著差异。我们认为，检测脑脊液tau蛋白可能有助于鉴别CBD和PSP。
